CAM
BIOA

Cormorant Asset Management’s BioAge Labs BIOA Stock Holding History

Cormorant Asset Management’s Portfolio BIOA Stock Details BIOA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$58.6M Sell
2,390,605
-500,000
-17% -$9.03M 3% 13
2026
Q1 		$50.6M Buy
2,890,605
+850,000
+42% +$16.4M 2.54% 14
2025
Q4 		$27M Sell
2,040,605
-100,000
-5% -$886K 1.25% 21
2025
Q3 		$12.6M Hold
2,140,605
– – 0.87% 27
2025
Q2 		$8.84M Sell
2,140,605
-488,924
-19% -$1.97M 0.66% 29
2025
Q1 		$9.89M Hold
2,629,529
– – 0.74% 30
2024
Q4 		$15.2M Buy
2,629,529
+1,000,000
+61% +$17.2M 0.84% 31
2024
Q3 		$33.9M Buy
+1,629,529
New +$32.7M 1.8% 21

Other funds holding BIOA

ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

Cormorant Asset Management's BIOA Position: Q2 2026 in Review

Cormorant Asset Management reduced its BioAge Labs (BIOA) stake by 17% in Q2 2026, selling an estimated $9.03M and leaving 2,390,605 shares worth $58.6M. The position accounts for 3% of the portfolio, ranked #13.

Cormorant Asset Management first reported a position in BIOA in Q3 2024 and has held it in 8 quarters since. 150 funds tracked by Wall St. Rank hold BIOA as of Q2 2026.

  • Cormorant Asset Management held 2,390,605 shares of BioAge Labs worth $58.6M as of Q2 2026.
  • Cormorant Asset Management sold 500,000 BioAge Labs shares in Q2 2026, an estimated $9.03M.
  • BioAge Labs made up 3% of Cormorant Asset Management's portfolio in Q2 2026, its #13 holding.
  • Cormorant Asset Management first reported a position in BioAge Labs in Q3 2024 and has held it in 8 quarters since.
  • 150 funds tracked by Wall St. Rank held BioAge Labs as of Q2 2026.

Based on Cormorant Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.